Cruiser Capital joins activist push for Ashland sale

Investors threaten board challenge if a sale is not pursued.

Activist investor Cruiser Capital Advisors has called on Ashland's board to pursue strategic alternatives, adding to growing shareholder pressure for the specialty chemicals company to consider a sale.

Cruiser argued that Ashland lacks the scale to maximize returns on its portfolio of businesses, according to a letter seen by Bloomberg, adding that a sale offers the strongest opportunity to enhance shareholder value by cutting overhead costs caused by Ashland’s standalone corporate structure.

The activist estimates that a potential acquirer could generate at least $100 million in cost savings, strengthening the case for a transaction.

Cruiser’s campaign follows pressure from fellow activist investor Ancora Holdings Group, which called on Ashland to evaluate strategic alternatives including a potential sale earlier this month.

Ancora argued that CEO Guillermo Novo’s efforts to streamline operations and boost performance have not been recognized by the market, noting a 24% stock price decline during his tenure.

The activist believes a sale could value the company at around $76 per share, warning that it may nominate directors if the company does not make progress towards exploring a sale before the nomination window opens in September.

Cruiser Capital has also warned that if the board has not begun a credible sale process by 15 September, it intends to nominate its own slate of directors in a proxy contest.

The involvement of multiple activists increases pressure on Ashland’s management to address whether the company’s current strategy represents the best route to maximize shareholder returns.

The situation also highlights the changing role of activist investors.

Rather than simply seeking board representation or operational changes, many activists are increasingly acting as catalysts for M&A activity, pushing companies towards break-ups, divestitures, and outright sales.

The key question facing Ashland now is whether to embrace a potential sale process or maintain its current strategy and potentially face increased investor intervention.

Like this article? Sign up for our free newsletter.